Crinetics Pharmaceuticals

Crinetics Pharmaceuticals works on 4 rare diseases tracked on Trial Friend, including Acromegaly, Congenital Adrenal Hyperplasia, Cushing Disease and 1 more, with 4 recruiting clinical trials and 1 FDA-approved rare disease drug.

Crinetics Pharmaceuticals is a San Diego biotech with one clear focus. They build oral pills for rare hormone diseases that, for decades, have been treated mostly with injections or imprecise hormone replacement. The company was started in 2008 by four scientists who left Neurocrine Biosciences (Scott Struthers, Stephen Betz, Frank Zhu, and Ana Kusnetzow) and went public on the NASDAQ in 2018 under the ticker CRNX. On July 6, 2026, Crinetics agreed to be acquired by Vertex Pharmaceuticals for $85.00 per share in cash (approximately $10 billion equity value). The transaction closed on September 1, 2026, and Crinetics is now part of Vertex. Its medicines and pipeline programs described below continue under Vertex.

Their first FDA approval came in September 2025, when Palsonify (the brand name for paltusotine) was approved for acromegaly. Acromegaly is a rare disorder where the body makes too much growth hormone, usually because of a small tumor on the pituitary gland. For most adult patients, the standard treatment had been monthly injections at a doctor's office for years on end. Palsonify is the first oral once-daily pill that works the same way the injections do, and in the Phase 3 PATHFNDR-1 trial, 83% of patients on Palsonify kept their hormone levels in the normal range compared to 4% on placebo. Crinetics runs a patient support program called CrinetiCARE that helps with insurance, copays, and getting started on treatment.

The next major drug in development is atumelnant, which is being studied for two related rare hormone diseases. Both classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome have historically forced patients to take very high doses of steroids to keep their disease under control. The high steroid doses do their job but they also cause serious long-term problems including heart disease, weight gain, weakened bones, and metabolic issues. Atumelnant takes a different approach by blocking the signal that tells the adrenal glands to overproduce, which could give patients a way to lower their steroid doses safely. The pivotal Phase 3 CALM-CAH adult trial dosed its first patient in December 2025, a Phase 2/3 pediatric trial called BALANCE-CAH started in January 2026, and the FDA has granted atumelnant Orphan Drug Designation for CAH.

Earlier in the pipeline, Crinetics is also developing an oral pill for congenital hyperinsulinism (a rare cause of dangerously low blood sugar in babies and young children) and has preclinical programs in hyperaldosteronism, thyroid eye disease, and polycystic ovary syndrome. The throughline across the company is consistent: find rare endocrine diseases where today's treatments rely on injections or blunt hormone replacement, and give patients a precise daily oral alternative that they can take at home instead of in a clinic.